- Home
- MNDO vs PASG Comparison
MNDO vs PASG Comparison
Compare MNDO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- PASG
- Stock Information
- Founded
- MNDO 1995
- PASG 2017
- Country
- MNDO Israel
- PASG United States
- Employees
- MNDO N/A
- PASG N/A
- Industry
- MNDO EDP Services
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- PASG Health Care
- Exchange
- MNDO Nasdaq
- PASG Nasdaq
- Market Cap
- MNDO 34.3M
- PASG 31.1M
- IPO Year
- MNDO 2000
- PASG 2020
- Fundamental
- Price
- MNDO $1.68
- PASG $0.34
- Analyst Decision
- MNDO
- PASG Strong Buy
- Analyst Count
- MNDO 0
- PASG 3
- Target Price
- MNDO N/A
- PASG $7.67
- AVG Volume (30 Days)
- MNDO 77.2K
- PASG 192.0K
- Earning Date
- MNDO 05-07-2025
- PASG 05-13-2025
- Dividend Yield
- MNDO 13.02%
- PASG N/A
- EPS Growth
- MNDO N/A
- PASG N/A
- EPS
- MNDO 0.22
- PASG N/A
- Revenue
- MNDO $21,446,000.00
- PASG N/A
- Revenue This Year
- MNDO N/A
- PASG N/A
- Revenue Next Year
- MNDO N/A
- PASG N/A
- P/E Ratio
- MNDO $7.59
- PASG N/A
- Revenue Growth
- MNDO N/A
- PASG N/A
- 52 Week Low
- MNDO $1.60
- PASG $0.30
- 52 Week High
- MNDO $2.13
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- MNDO 37.41
- PASG 41.07
- Support Level
- MNDO $1.65
- PASG $0.31
- Resistance Level
- MNDO $1.69
- PASG $0.40
- Average True Range (ATR)
- MNDO 0.07
- PASG 0.05
- MACD
- MNDO 0.00
- PASG 0.00
- Stochastic Oscillator
- MNDO 38.10
- PASG 30.00
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.